Tag: Biotech and Pharma

Αύξηση των ενοποιημένων πωλήσεων παρουσιάζει ο Όμιλος Lavipharm κατά το α’ εξάμηνο του 2024. Συγκεκριμένα, οι ενοποιημένες πωλήσεις από συνεχιζόμενες δραστηριότητες ανήλθαν σε 30,6 εκατ. ευρώ έναντι 29,1 εκατ. ευρώ το αντίστοιχο διάστημα του 2023, σημειώνοντας αύξηση κατά 5,3%.

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business.

Bavarian Nordic said on Thursday it could supply 13 million doses of its mpox vaccine by the end of 2025, up from a previous forecast of 10 million doses, and is exploring options to significantly expand its capacity.

Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland

The drug Liraglutide was shown in a Novo-sponsored late-stage clinical trial to have reduced the body-mass index (BMI) in children aged between 6-11.

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

Merck  stock fell early Monday after a rival pharmaceutical company said its cancer drug beat Merck’s Keytruda in a head-to-head trial.

The World Health Organization earlier this month declared the Mpox outbreak a public-health emergency of international concern. (Dreamstime) were charging higher after the vaccine maker announced the Food and Drug Administration approved its smallpox vaccine for Mpox disease in individuals at high risk for infection.

GSK shares jumped Wednesday on news Delaware’s top court ruled in the pharmaceutical company’s favor, by agreeing to review the admissibility of expert evidence that could play a part in the British firm’s legal fight against claims its Zantac heartburn drug causes cancer.

Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare

Shares of Danish biotech company Bavarian Nordic jumped 13% on Thursday after it reported stronger-than-expected earnings and announced a bumper vaccine order from an unnamed European country amid the ongoing mpox outbreak.

Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday.

GeoVax Labs Inc.’s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.

Bayer shares jumped in morning trade as the German life sciences company said it scored a legal victory in its suit over claims that exposure to its popular Roundup weed killer led to cancer.

Danish biotech company Bavarian Nordic said Friday that it had submitted data to the Europe Union’s drug regulator to extend the use of its mpox vaccine for teenagers.

The biotech Gilead Sciences raised its earnings guidance Thursday while reporting second quarter results that beat Wall Street expectations, as the company continues to battle back from an early-year slump in its share price.

Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike.

 Novavax on Thursday cut its revenue forecast for 2024 as it anticipated lower sales of its COVID-19 vaccine, including the company’s updated shot for the fall season targeting the JN.1 variant.

Novo Nordisk on Wednesday posted weaker-than-expected net profit in the second quarter and trimmed its operating profit outlook.

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company’s cost cuts showed progress and sales of its breakthrough Alzheimer’s drug, Leqembi, and other new products beat expectations.